Abbott India Ltd (ABBOTINDIA) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Abbott India Ltd, a branded formulations pharmaceutical company with leadership positions across Gastrointestinal, Women's Health, Metabolics, CNS and Vaccines, reports into an Indian Pharmaceutical Market that grew over 10% in value through July-August 2026 while its own Q1 revenue rose just 4.33%. The print will speak to whether the company's growth narrows the gap with a price-led market, and whether Q1's margin expansion — flagged as partly a temporary inventory-FX benefit — holds as the purchases ratio reverts.

Abbott India Ltd Q2 Results Date and Time

The Board of Directors will meet on Thursday, November 5, 2026, to consider and approve unaudited financial results for the second quarter and half-year ended September 30, 2026. The trading window for designated persons remained closed from October 1 to November 7, 2026 (both days inclusive).

What to expect from Abbott India Ltd's Q2 FY27 results

The quarter tests whether Abbott India can close the growth gap with a strong market: the Indian Pharmaceutical Market grew +12.1% in July and +10.7% in August 2026 on PharmaTrac data, while Abbott entered Q2 having grown +4.33% in Q1 FY27, below both the market and its own FY26 pace of +8.1%.

Margin is the second axis — Q1's expansion of 314 bps YoY to a 32.96% EBITDA margin was flagged as partly a temporary inventory-FX benefit, with the purchases ratio expected to revert to 48-50% as old stock is replaced. Cost items add a live variable: the four Labour Codes, which drove an incremental Rs. 18.10 Crores charge in FY26, were still mid-rollout during the quarter, with ten states having published rules by September 24, 2026.

On Metabolics, the Novo Nordisk-licensed Extensior GLP-1 launch faces a widening generic field — the four innovator brands including Extensior held about 50% of an estimated Rs. 400 Cr semaglutide injectable market in July, while Torrent's entrants took a 36% share of the combined market in Q1 FY27. Management's stated priorities remain sustaining growth while preserving margin quality and maintaining a sharp focus on cash generation, following a FY26 in which it stated 'EBITDA improved from 31% to 32%'.

Key Things To Watch

Performance vs guidance tracking: All operative commitments are qualitative from the FY26 annual report — the call is the first checkpoint on each.

• Sustained new product launches and portfolio expansion across key therapeutic areas — by FY 2026-27 — five launches delivered in FY26, cadence update pending
• Deepen presence in Tier 2 and Tier 3 markets — by FY 2026-27 — progress update pending
• Margin preservation via operating discipline, productivity and portfolio optimisation — open-ended guidance, now tested against the purchases-ratio reversion
• Cash generation and capital efficiency — open-ended guidance, against a post-dividend cash rebuild from the Rs. 2,254.95 Cr March-2026 cash-and-bank base

Margin bridge and cost items

• How much of Q1's temporary inventory-FX margin benefit reversed; purchases ratio versus the guided 48-50% reversion
• Any incremental gratuity or compensated-absences charge as state Labour Code rules lock in — FY26 took Rs. 18.10 Crores (Gratuity Rs. 15.70 Crores; Compensated Absences Rs. 2.40 Crores)
• Finance costs trajectory under Ind AS 116 — FY26 finance costs rose +118.64% YoY on lease interest

Extensior GLP-1 ramp

• Uptake versus the July innovator-brand print — four brands including Extensior did Rs. 46 Cr collectively, about 50% share of an estimated Rs. 400 Cr semaglutide injectable market
• Pricing posture as generic entrants scale — Torrent's Sembolic/Semalix took a 36% share of the combined semaglutide market in Q1 FY27, with Dr Reddy's supplies returning from late October after an API impurity issue

Women's Health dydrogesterone pressure

• Whether pricing and generic pressure in dydrogesterone stabilised — management flagged 'category stagnation and increasing generic competition' in FY26
• Progress in fertility, contraception and menopause expansion anchored by Duphaston and Femoston

Dividend outflow, cash rebuild and regulatory follow-up

• Cash rebuild after the Rs. 1,393.96 Crore FY26 dividend (Rs. 656/share including Rs. 131 special), approximately 90% of FY26 PAT; Current Ratio declined from 3.37 to 2.55
• Appeal status of the Rs. 2,40,46,491 GST penalty levied by the Additional Commissioner, GST & Central Excise, Mumbai East
• First results period with Mr. Sudarshan Jain as Chairman, effective August 13, 2026, succeeding Mr. Munir Shaikh